ArticleJapanese journal of cancer research : Gann1992
p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas.
Article in Japanese journal of cancer research : Gann, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 138 citations in OpenAlex.
- 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.Thyroid : official journal of the American Thyroid Association · 2021Guideline
- Review
- Epigenomic Modulators and Thyroid Hormone Receptor β Agonists: A New Paradigm for Tumor Suppression in Thyroid Cancer.Endocrinology · 2025Review
- Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation.Oncotarget · 2024Article
- Progress in Thyroid Cancer Genomics: A 40-Year Journey.Thyroid : official journal of the American Thyroid Association · 2023Review
- Radiotherapy combined with immunotherapy successfully treated one case of anaplastic thyroid cancer: A case report.Frontiers in oncology · 2023Article
- Novel role of ASH1L histone methyltransferase in anaplastic thyroid carcinoma.The Journal of biological chemistry · 2020Article
- Molecular therapeutics for anaplastic thyroid cancer.Seminars in cancer biology · 2020Article
- Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.Nature reviews. Endocrinology · 2017Review
- Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.The Journal of clinical investigation · 2016Article
- Genetics and epigenetics of sporadic thyroid cancer.Molecular and cellular endocrinology · 2014Review
- Establishment, characterization and comparison of seven authentic anaplastic thyroid cancer cell lines retaining clinical features of the original tumors.World journal of surgery · 2014Article
- Essential genes in thyroid cancers: focus on fascin.Journal of diabetes and metabolic disorders · 2013Article
- Anaplastic transformation of differentiated thyroid carcinoma.International journal of health sciences · 2009Article
- Controversies in thyroid pathology: the diagnosis of follicular neoplasms.Endocrine pathology · 2008Review
- Down-regulation of an inhibitor of cell growth, transmembrane protein 34 (TMEM34), in anaplastic thyroid cancer.Journal of cancer research and clinical oncology · 2007Article
- Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer.BMC cancer · 2006Article
- Decreased expression of haemoglobin beta (HBB) gene in anaplastic thyroid cancer and recovery of its expression inhibits cell growth.British journal of cancer · 2005Article
- Anaplastic thyroid cancer and hyperthyroidism.Endocrine pathology · 2005Article
- Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas.Endocrine pathology · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaplastic carcinoma of the thyroid gland, which is one of the most aggressive, malignant tumors in humans, is considered to originate from preexisting differentiated thyroid cancer. To define the genetic alterations associated with such progression, we examined nine cases of anaplastic thyroid carcinoma for mutation in exons 4-9 of the p53 tumor suppressor gene. Preliminary screening for mutation by RNase protection analysis demonstrated that two out of nine anaplastic carcinomas contained sequence alterations in the p53 gene. Subsequent DNA sequencing identified the mutated nucleotides in these two cases; one was a nonsense mutation at codon 165, and the other was a single-base deletion at codon 176 resulting in the creation of a stop codon downstream due to frameshift. The fact that no mutations were detected in coexisting foci of papillary carcinomas from the same patients shows that these mutations of the p53 gene occurred after development of papillary carcinomas. These results suggest that p53 gene mutation triggers the progression from differentiated into anaplastic carcinoma in the human thyroid gland.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.